Foghorn Therapeutics vs Scilex
Foghorn Therapeutics reported revenue of $31 million in fiscal 2025, about the same as Scilex's $30 million in fiscal 2025. Foghorn Therapeutics' revenue grew 36.8% in its latest year, and Scilex's fell 46.5%. Foghorn Therapeutics had an operating margin of -279.5%, against -1143.7% at Scilex. Free cash flow was −$86 million at Foghorn Therapeutics and $4 million at Scilex.
Side by side
| Foghorn Therapeutics | Scilex | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $31M | $30M |
| Revenue growth | 36.8% | −46.5% |
| Revenue growth a year, last 5 years | 138.6% | 5.1% |
| Gross margin | — | — |
| Operating margin | −279.5% | −1,143.7% |
| Net margin | −240.3% | −1,236.4% |
| Free cash flow | −$86M | $4M |
| Free cash flow margin | −278.7% | 12.2% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 14.7% | 108,662.9% |
| Last close | $1.78 | $0.65 |
| P/E at the last close | 25.4× | — |
| Insider trades, last 12 months | — | sold $12.8 million |
| Piotroski F-score | 2 of 8 | 3 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Foghorn TherapeuticsScilex
Operating margin
Percent of revenue
Foghorn TherapeuticsScilex
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Foghorn TherapeuticsScilex
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Foghorn Therapeutics and Scilex pages.